Compared to the persistent RAS-mut group, patients in the NeoRAS-wt group were more likely to be diagnosed with early-stage disease (69.3% vs. 25.9% stage II-III CRC) and had more rectal adenocarcinomas (38.5% vs. 11.5%), higher number of metastatic sites (61.5% vs. 30.8% ≥2 metastatic sites), and lower CEA at the time of detection of metastatic disease (46.2% vs. 34.5% CEA < 3.5 ng/mL). The gene discussed is CEACAM5; the disease is metastatic neoplasm.